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Abstract
Early detection of obesity-related glomerulopathy in humans is challenging as it might not
be detected by routine biomarkers of kidney function. This study’s aim was to use novel kid-
ney biomarkers and contrast-enhanced ultrasound (CEUS) to evaluate the effect of obesity
development and weight-loss on kidney function, perfusion, and injury in dogs. Sixteen
healthy lean adult beagles were assigned randomly but age-matched to a control group
(CG) (n = 8) fed to maintain a lean body weight (BW) for 83 weeks; or to a weight-change
group (WCG) (n = 8) fed the same diet to induce obesity (week 0–47), to maintain stable
obese weight (week 47–56) and to lose BW (week 56–83). At 8 time points, values of sys-
tolic blood pressure (sBP); serum creatinine (sCr); blood urea nitrogen (BUN); serum cysta-
tin C (sCysC); urine protein-to-creatinine ratio (UPC); and urinary biomarkers of glomerular
and tubular injury were measured. Glomerular filtration rate (GFR) and renal perfusion using
CEUS were assayed (except for week 68). For CEUS, intensity- and time-related parame-
ters representing blood volume and velocity were derived from imaging data, respectively.
At 12–22% weight-gain, cortical time-to-peak, representing blood velocity, was shorter in
the WCG vs. the CG. After 37% weight-gain, sCysC, UPC, glomerular and tubular biomark-
ers of injury, urinary immunoglobulin G and urinary neutrophil gelatinase-associated lipoca-
lin, respectively, were higher in the WCG. sBP, sCr, BUN and GFR were not significantly
different. After 23% weight-loss, all alterations were attenuated. Early weight-gain in dogs
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induced renal perfusion changes measured with CEUS, without hyperfiltration, preceding
increased urinary protein excretion with potential glomerular and tubular injury. The com-
bined use of routine biomarkers of kidney function, CEUS and site-specific urinary biomark-
ers might be valuable in assessing kidney health of individuals at risk for obesity-related
glomerulopathy in a non-invasive manner.
Introduction
Besides diabetes and hypertension, excess weight in the form of adipose tissue also increases
the risk of developing obesity-related glomerulopathy and chronic kidney disease in humans
[1]. Obesity-related glomerulopathy is characterized by glomerulomegaly, focal segmental glo-
merulosclerosis, hyperfiltration and subnephrotic to nephrotic-range proteinuria [2]. Weight-
loss improves proteinuria and albuminuria in overweight and obese humans with chronic kid-
ney disease [3]. Although the mechanism of how excess weight can lead to chronic kidney dis-
ease is not fully understood, physical (e.g., fat accumulation and ectopic fat in kidney),
inflammatory (e.g., adipokines like leptin) and renal hemodynamic factors (e.g., increased glo-
merular filtration rate (GFR) and renal blood flow due to increased tubular sodium reabsorp-
tion) might play important roles [2].
Because of the kidney’s compensatory ability, obesity-related kidney injury can develop
asymptomatically and might not be detected either by routine kidney function biomarkers
(e.g., serum creatinine, blood urea nitrogen (BUN)) or by GFR measurements early in the dis-
ease [4]. Obesity-related glomerulopathy confirmation relies on renal biopsies, which are inva-
sive [5]. Therefore, more sensitive and/or site-specific biomarkers of kidney injury and
function that can aid in the early detection, monitoring, and potentially prevention of obesity-
related glomerulopathy are needed [4]. Serum cystatin C (sCysC), for example, is a surrogate
GFR marker less affected by external factors, e.g., muscle mass, than serum creatinine [6]. In
dogs, biomarkers of glomerular injury, urinary immunoglobulin G (uIgG) and C-reactive pro-
tein (uCRP); and biomarkers of tubular injury urinary, retinol-binding protein (uRBP) and
neutrophil-gelatinase-associated lipocalin (uNGAL), have shown potential to distinguish
healthy animals from animals with kidney disease [7–10]. In humans, uIgG, uRBP, and
uNGAL can detect diabetic nephropathy in an early stage [11].
Because microvascular disease might play a role in obesity-related glomerulopathy develop-
ment, tools to evaluate early changes in renal microcirculation could also be helpful [12]. Con-
trast-enhanced ultrasonography (CEUS) utilizing gas-filled microbubbles enables non-
invasive and -toxic real-time measurement of renal perfusion at both the macro- and micro-
vascular level [13]. Furthermore, in humans, renal cortical perfusion assessed by CEUS paral-
lels effective renal plasma flow [14]. In human studies, CEUS could distinguish those in early
stages of chronic kidney disease from healthy volunteers [13]. In a murine model of obesity-
related glomerulopathy, CEUS detects increased cortical perfusion time, accompanied by a
decrease in cortical microvessel density [15].
The aim of this study was to use CEUS and a set of selected sensitive and site-specific renal
biomarkers to assess when and how changes in kidney function, perfusion and injury occur
during gradual diet-induced obesity and subsequent weight-loss in dogs. Plasma clearance of
exo-iohexol was used as a gold standard for renal function. Although animal models demon-
strate that obesity can cause kidney injury and dysfunction [15–18] and human studies show
that weight-loss can improve kidney function [3,19,20], to our knowledge, no study has
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examined kidney function and injury during the development of obesity and after weight-loss
in the same individual yet. Furthermore, using dogs, which have been previously used as mod-
els for the study of diet-induced obesity and the kidney [17,21–23], allows for a highly con-
trolled study that is otherwise difficult to perform with human subjects.
Methods
Animals and experimental protocol
This longitudinal study of approximately 1.5 years was approved by the Institutional Animal
Ethics Committee (Faculties of Veterinary Medicine and Bioscience Engineering, Ghent Uni-
versity, Belgium; EC2016/92) and performed in accordance with European (European Direc-
tive (2010/63/EU)) and national guidelines for the care and use of animals. Sixteen lean
purpose-bred adult beagles (mean (standard deviation (SD)), 4.4 (2.0) years; six intact and two
spayed females, four intact and four neutered males) were housed in controlled kennel condi-
tions (12:12 h light-dark cycle). All dogs were considered healthy based on their medical his-
tory, on physical examination, complete blood count, serum biochemistry profile, abdominal
ultrasonography, routine urinalysis (sediment examination, dipstick analysis, specific gravity
measurement), urine protein-to-creatinine ratio (UPC) and urine bacterial culture.
After adapting to a commercial adult maintenance dry diet (Veterinary™ HPM Adult Large
and Medium, Virbac, Carros, France) for four weeks, the dogs were equally divided into two
groups, randomly, matched by age and sex. In the control group, eight beagles were fed to
maintain a lean body weight and body condition score (BCS 4-5/9) for 83 weeks [24]. Part of
the dataset from these eight beagles were published by Liu et al [25,26]. The body condition
scoring system based on 9-points used in this study is a validated method to semi-quantitively
assess the body composition of dogs base on visual and palpable characteristics [24]. The sys-
tem ranges from 1 which stands for cachectic to 9 which stands for severely obese. A BCS of 4
or 5 represents an ideal body composition [24]. Individual maintenance energy requirements,
based on the National Research Council requirement of 552 kJ/kg0.75, were adjusted when
needed to maintain lean body weight [27]. Based on the protocol of a previous canine obesity
study [28], the other eight beagles of the weight-change group were initially fed 1.3 x mainte-
nance energy requirements using the same diet as the control group to gradually induce obe-
sity (week 0 to 47) and adjusted when needed. Overweight was defined as having a BCS of 6 or
7/9 and obesity as a BCS of 8 or 9/9 (ref. 24). From week 47 to 56, the amount of food was ini-
tially reduced 10%, and hereafter adjusted to maintain a stable body weight. From week 56 to
83, the weight-change group was initially fed resting energy requirements (293 kJ/kg0.75, based
on week 0 body weight as ideal body weight) to induce weight-loss. The amount was adjusted
weekly to maintain a gradual weight-loss rate of 0.5–2% per week. The analyzed nutrient com-
position of the diet is shown in S1 Table. The dogs were fed individually once a day and had
free access to water. Food intake was recorded daily. body weight and BCS were evaluated
weekly.
Measurements were made after the adaptation period at week 0, 12, 24, 36, 47, 56, 68 and
83 and performed over two weeks. A schematic representation of the study protocol is shown
in Fig 1. During the first week of each time point, systolic blood pressure (sBP) was measured
on the first over two days in the first week. The next three days dogs were fasted and blood
samples (12 mL) were collected from the jugular vein (21G needle), and GFR was measured.
On the third and fourth day of the second week, morning urine samples (10 mL) were col-
lected by ultrasound-guided cystocentesis (22G needle) without sedation, followed by CEUS
under sedation. On the last day of the week body composition was determined. All are meth-
ods described below. During week 68, only sBP, blood sampling and cystocentesis were
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performed and completed within 3 days. Complete blood count and serum biochemistry
(Architect C16000, Abbott Max-Planck-Ring, Wiesbaden, Germany) were repeated at week
24, 47, 56 and 83. Serum creatinine concentrations were considered normal when <1.4 mg/dL
[29]. BUN values were considered normal when between laboratory ranges (6–57 mg/dL).
Blood samples were centrifuged at 2000 × g for 5 min at 21˚C within 2 h of collection and
serum divided into 250 μL aliquots for sCysC and serum leptin. An aliquot of morning urine
(5 mL) was used for urinalysis (dipstick analysis, specific gravity, UPC (Iricell IQ; Instrumenta-
tion Laboratory, Zaventem, Belgium); sediment analysis (IQ 200 SPRINT, Instrumentation
Laboratory, Zaventem, Belgium); and bacterial culture). A UPC value greater than 0.5 was
defined as proteinuria [29]. Another 5 mL of urine was centrifuged at 450 × g for 3 min at
21˚C. The supernatant was stored in 200 μL aliquots within 30 minutes of collection for uri-
nary biomarkers. Both serum and urine samples were stored at -80˚C. The dogs were not sacri-
ficed at the end of the study.
Measurement of systolic blood pressure and GFR. sBP was measured indirectly using
the Doppler technique (Parks Medical Electronics Inc., Aloha, OR, USA) on the right forelimb
according to the recommended procedures of the consensus statement of the American Col-
lege of Veterinary Internal Medicine [30]. Systemic hypertension was defined as sBP> 150
mmHg [30].
Fig 1. Schematic representation of the study protocol. (A) Summary of the sample points and timeline of the
procedures used during the entire study for both the control and the weight-change groups. The control group was fed
to maintain a stable body weight. The weight-gain group was fed to gain weight (WG), to remain at a stable weight
(WS), and to lose weight (WL) in three consecutive phases. The procedures performed were measurement of systolic
blood pressure (sBP), glomerular filtration rate (GFR), blood and urine collection, contrast-enhanced ultrasonography
(CEUS) and body composition analysis (BC). (B) Timeline of the procedures during each sample point, except for
week 68 when all procedures were performed within 3 days, starting measurement of sBP and ending with blood and
urine collections.
https://doi.org/10.1371/journal.pone.0231662.g001
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After a 12 h fast, GFR was measured (mGFR) by determination plasma clearance of exo-
iohexol after an intravenous bolus administration of iohexol (64.7 mg/kg body weight, Omni-
paque 3001, GE healthcare, Diegem, Belgium), as previously described [10,31]. Plasma was
divided into 300 μL aliquots and stored at -20˚C. Clearance of exo-iohexol was determined by
noncompartmental analysis using Phoenix 6.4 (Princeton, NJ, USA).
CEUS examination and quantitative analysis. Prior to CEUS examinations, dogs were
fasted for 12 h. CEUS under sedation (0.4 mg/kg, Dolorex1 10 mg/ml, MSD, Mechelen, Bel-
gium) was performed on all dogs in a standardized manner, following the protocol described
in Liu et al [25]. Briefly, the same linear transducer (12–5 MHz) and settings (single focus
directly under the kidney, image depth 5 cm, persistency off, mechanical index 0.08, dynamic
range C50, gain 85%, frame rate 8 Hz, and side-by-side imaging) on a dedicated machine
(iU22) with contrast-specific software were used for all contrast-enhanced ultrasound evalua-
tions. The transducer was held manually in a longitudinal plane on the kidney and in the same
position. All ultrasound imaging was performed by one of the co-authors (E.S.). Commercially
available sulfur hexafluoride-filled microbubbles (SonoVue1, Bracco Diagnostics Inc., Milan,
Italy) were prepared and administered as a bolus (0.04 mL/kg) following the manufacturer’s
guidelines (D.L. and K.V.). Microbubbles were injected into a catheter through a three-way
stopcock, followed immediately by 2 mL of sterile saline. Simultaneously with the injection,
the timer was set at 0 and a 90-s digital recording was made. Between each injection, micro-
bubbles were destroyed by scanning the caudal abdominal aorta at a mechanical index of 0.5.
The left kidney was imaged first and twice, followed by the right kidney, which was imaged
once. A bolus was repeated if a large movement artifact was present. The recording from the
second bolus of the left kidney was used for further evaluation [32]. An example of a recording
can be seen in S1 Video.
The CEUS clips were analyzed using specialized computer software (VueBox, Bracco Suisse,
Switzerland) for objective quantitative analysis by first author. The quantification protocol was
previously described by Liu et al [25]. Briefly, three region-of-interests (ROI) were manually
drawn, keeping the area and depth for each location approximately the same for every dog at
all time points (Fig 2). The software generated time-intensity curves and determined mean
pixel intensities for each ROI. Intensity-related parameters representing blood volume and
time-related parameters representing blood velocity were determined from the time-intensity
curve. The definition for each parameter is presented in Fig 3.
Body composition determination. Body composition was determined by isotopic dilu-
tion of deuterium oxide using Fourier-transform infrared spectroscopy as previously described
[28,34]. Samples were centrifuged at 2000 × g for 5 minutes at 21˚C and plasma stored in
300 μL aliquots at -20˚C.
Determination of serum leptin, sCysC and urinary biomarkers. Following manufactur-
er’s instructions, serum leptin concentration was measured using a validated, commercially
available canine ELISA kit (Millipore Corp., Billerica, MA, USA) in one batch [35]. The limit
of detection and of quantification for this kit was 1.04 ng/mL and 1.88 ng/mL, respectively.
Immunoassays for sCysC, uCRP, uIgG, uNGAL and uRBP have been described in detail
elsewhere [26]. The concentration of each urinary biomarker was expressed as a ratio to uri-
nary creatinine (/c) to account for variations in urine concentration [36].
Statistical analysis
For the immunoassays, statistical handling of data from samples below the limit of detection
or between the limit of detection and of quantification were published in Liu et al [26].
PLOS ONE Renal assessment during weight-gain and -loss
PLOS ONE | https://doi.org/10.1371/journal.pone.0231662 April 21, 2020 5 / 20
A stepwise analysis was conducted. First, associations between body characteristics (body
fat % and lean mass; dependent variables) and independent variables serum leptin, markers of
kidney function and kidney injury, and CEUS renal perfusion parameters were analyzed
within the weight-change group using a linear mixed model with dog as random effect. Vari-
ables with significant associations (P< 0.05) with either of the body characteristics were used
next in a linear mixed model where the significance of the interaction between group and time
was evaluated to compare both groups over time. For the CEUS parameters, kidney depth was
accounted for in the mixed models (fixed effect). Dog and kidney side were included as ran-
dom effects. When the interaction was significant, a post hoc comparison for each time point
was conducted and a Bonferroni correction was consistently applied to account for multiple
testing. The results are presented as mean ± SD for body characteristics, sBP, serum leptin,
serum creatinine, BUN, mGFR, UPC, sCysC and the urinary biomarkers; and for the CEUS
parameters of the cortex and medulla of both groups or median (minimum–maximum) for
BCS. All statistical analyses were conducted in R version 3.4.4. In all mixed models, the default
variance-covariance structure of the lme4-package was used.
Results
One of the control dogs was diagnosed with multicentric lymphoma 1 month after the week
56 measurements and was euthanized. Necropsy confirmed the diagnosis of multicentric lym-
phoma with pulmonary and hepatic involvement, but there were no signs of lymphoma infil-
tration in the kidney. Therefore, data from this dog were kept for statistical analysis. At week
24, urine collection and CEUS was not possible for another control dog because it was briefly
hospitalized for injury unrelated to the study (i.e., eye trauma).
Fig 2. A contrast-enhanced ultrasound image of a left kidney in the sagittal plane of dog with region-of-interests
drawn in the renal cortex (yellow line), renal medulla (magenta line) and on the entire kidney (green line). The
size of region-of-interests, from which time-intensity curves were generated, were 0.51 cm2 for the cortex and 0.37 cm2
for the medulla.
https://doi.org/10.1371/journal.pone.0231662.g002
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Body characteristics
At week 0, the control group and weight-change group dogs weighed 11.6 ± 1.7 kg and
11.2 ± 2 kg, and had 14.6 ± 6.1% and 15.8 ± 7.1% body fat, respectively. They had a lean BCS of
4 (4–4 and 4–5, respectively).
After 47 weeks of feeding 1.4 ± 0.5 x maintenance energy requirements (869 ± 156 kJ/kg0.75
ideal body weight), three dogs were overweight and five were obese in the weight-change
group (BCS 8/9 (6–9)) with a 36.8 ± 16.6% gain in body weight. Body fat increased
16.8 ± 7.7%, which was equivalent to a body fat % of 32.6 ± 5.1%. The values of body weight
(week 24: 12.0 ± 1.7 vs. 13.7 ± 2.3 kg, week 36: 12.7 ± 1.7 vs. 15.0 ± 2.6 kg, week 47: 11.9 ± 1.4
vs. 15.3 ± 3.0 kg, week 56: 12.1 ± 2.0 vs. 15.9 ± 3.4 kg; all P< 0.001), body fat % (week 12:
14.1 ± 5.5 vs. 24.7 ± 4.9%, week 24: 16.4 ± 4.6 vs. 29.3 ± 4.7%, week 36: 17.5 ± 5.8 vs.
30.7 ± 7.5%, week 47: 17.2 ± 6.4 vs. 32.6 ± 5.1%, week 56: 15.5 ± 4.8 vs. 34.7 ± 5.2%; all
P< 0.001) and BCS (week 24: 4 (4–4) vs. 6.5 (5–7), week 36: 4 (4–5) vs. 8 (5–8), week 47: 4 (4–
5) vs. 8 (6–9), week 56: 4 (3–4) vs. 8 (6–9); all P < 0.001) were significantly higher in the
weight-change group compared to the control group from week 12 to 56 (Fig 4A–4C, 4E).
From week 47 to 56, the weight-change group continued to gain body weight and body fat
Fig 3. Schematic representation of a time intensity curve of the kidney. The x-axis represents the time in seconds (s)
and the y-axis represents the intensity in arbitrary units (a.u.). Intensity-related parameters are as follows: peak
enhancement (PE) referring to maximum enhancement; wash-in area under the curve (WiAUC) and wash-out area
under the curve (WoAUC) referring to the sum of all amplitudes inside the range from the beginning of the curve up
to the time-to-peak (TTP) and from the TTP to the end of the descending curve, respectively; and total area under the
curve (AUC)). Time-related parameters are as follows: rise time (RT) referring to the time interval between the first
arrival of contrast and TTP; mean transit time (mTT) representing the mean duration of complete contrast perfusion,
refers to the time when the tissue begins to enhance with contrast medium until the enhancement is half of the PE;
TTP referring to the time of contrast agent injection to maximum enhancement; fall time (FT) referring to the
duration of contrast wash-out) were determined from the time intensity curves. The slopes of the time-intensity curve
are wash-in (WiR) and wash-out rate (WoR) referring to the maximum and minimum slopes, respectively. Wash-in
perfusion index (WiPI) is calculated as WiAUC divided by RT. Adapted from the VueBox user manual with
permission [33].
https://doi.org/10.1371/journal.pone.0231662.g003
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despite a slight decrease in energy intake (843 ± 127 kJ/kg0.75 ideal body weight). Lean mass
(kg) also significantly increased at these two time points while the BCS remained stable (week
47: 9.9 ± 1.8 vs. 10.2 ± 2.4 kg, P = 0.018; week 56: 9.8 ± 1.9 vs. 10.0 ± 2.5 kg, P = 0.040)
(Fig 4D). During weight-loss (week 68–83), energy intake of the weight-change group was
548 ± 146 kJ/kg0.75 ideal body weight. By week 83, the weight-change group lost 23.4 ± 6.8% of
body weight and the BCS was 4/9 for all dogs. The body fat % of this group also decreased
from week 56 to 83 (-14.0 ± 4.2%). In contrast, the BCS of the control group remained within
the ideal range (BCS 4–5) throughout the study, except for one dog at week 56 (with BCS 3).
Energy intake throughout the study was 659 ± 156 kJ/kg0.75 based on ideal body weight.
Clinical characteristics and associations within the weight-change group
Results for sBP, serum leptin, serum creatinine, BUN, mGFR, UPC, sCysC and the urinary
biomarkers; and for the CEUS parameters of the cortex and medulla of both groups are
Fig 4. Body characteristics of beagles in the control (closed circles; n = 8) and weight-change (open circles; n = 8)
group during the weight-gain phase (week 0–47), weight-stable phase (week 47–56) and weight-loss phase (week
56–83). Body weight (kg) (A), % body weight gain (B), % body fat (C) and body condition score (E) increased
significantly from week 12 or week 24 until week 56 in the weight-change group compared to the control group. Lean
mass (kg) was significantly increased at week 47 and 56 in the weight-change group. Data is shown as mean ± SD.
aData from one dog missing in the control group. ���P = 0–0.001, ��P = 0.001–0.01 and �P = 0.01–0.05 for the group x
time interaction, after multiple correction.
https://doi.org/10.1371/journal.pone.0231662.g004
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reported in Table 1, S2 and S3 Tables. uCRP concentrations were below the detection limit of
the assay for all samples (5.28 ng/mL). Because of the large number of variables examined in
this study, parameters that were most likely influenced by obesity over time were first identi-
fied in the weight-change group (Table 2). No significant associations with body characteristics
(body fat % and lean mass) were found for sBP, serum creatinine, BUN and uRBP/c. Values of
serum creatinine and BUN for all dogs were <1.4 mg/dL and within laboratory reference
ranges throughout the study, respectively. Serum leptin and sCysC were significantly and posi-
tively correlated with both body fat % and lean mass (P < 0.05). Of the other kidney-related
measurements, an increase in body fat % was related to an increase in UPC, uIgG/c and
uNGAL/c, and a decrease in mGFR (P< 0.05). In the cortex, intensity-related parameters PE,
WiAUC, WoAUC and AUC were mainly negatively correlated with body fat %, while time-
related parameters were mainly negatively correlated with lean mass (P < 0.05). Only TTP was
negatively correlated with both body fat % and lean mass (P < 0.05). In the medulla, PE, WiR,
WiPI and WoR increased as lean mass increased (P< 0.05).
Serum leptin, kidney function and injury, and CEUS renal perfusion
variables of the control group and weight-change group over time
Serum leptin concentrations of the weight-change group were significantly higher at week 36
(0.64 ± 0.34 vs. 2.39 ± 1.39 ng/mL, P = 0.002), 47 (0.52 ± 0.00 vs. 2.66 ± 1.30 ng/mL, P < 0.001)
and 56 (0.64 ± 0.34 vs. 3.15 ± 1.68 ng/mL, P< 0.001) compared to the control group and
decreased after weight-loss (Table 1).
No significant differences were found between both groups for exo-iohexol plasma clear-
ance, as marker for mGFR, over time. Both sCysC and UPC levels, however, were significantly
higher in the weight-change group than in the control group at week 47 (sCysC: 0.14 ± 0.1 vs.
0.19 ± 0.1 mg/L, P = 0.011; UPC: 0.18 ± 0.14 vs. 0.56 ± 0.76, P = 0.038) and 56 (sCysC:
0.15 ± 0.1 vs. 0.19 ± 0.1 mg/L, P = 0.019; UPC: 0.21 ± 0.19 vs. 0.57 ± 0.61, P = 0.034) (Fig 5A
and 5B). At week 83, sCysC and UPC levels of the weight-change group decreased.
Table 1. Systolic blood pressure (sBP), serum leptin, serum creatinine (sCr), blood urea nitrogen (BUN) and glomerular filtration rate (mGFR) measured by exo-
iohexol plasma clearance over time in the control group (CG) and the weight-change group (WCG) in dogs.
Group Week 0 Week 12 Week 24 Week 36 Week 47 Week 56 Week 68 Week 83
sBP (mm Hg) CG 153.6 ± 15.9 136.5 ± 10.9 147.3 ± 8.8 131.3 ± 11.5 136.3 ± 11.3 138.5 ± 10 136.2 ± 10.5a 131.5 ± 6.2a
WCG 157.0 ± 14.4 141.2 ± 9.0 154.2 ± 8.3 144.7 ± 11.2 148.8 ± 13.5 155.2 ± 13.5 144 ± 8.9 139.5 ± 8.3
Serum leptin (ng/mL) CG 0.52 ± 0.00 0.52 ± 0.00 0.64 ± 0.34 0.64 ± 0.34 0.52 ± 0.00 0.64 ± 0.34 0.52 ± 0.00a 0.79 ± 0.46a
WCG 0.64 ± 0.34 0.99 ± 0.51 1.84 ± 0.70 2.39 ± 1.39§ 2.66 ± 1.30� 3.15 ± 1.68� 0.99 ± 0.51 0.76 ± 0.44
sCr (mg/dL) CG 0.63 ± 0.05 0.59 ± 0.07 0.61 ± 0.06 0.63 ± 0.06 0.61 ± 0.06 0.59 ± 0.09 0.64 ± 0.08a 0.69 ± 0.10a
WCG 0.63 ± 0.07 0.59 ± 0.11 0.59 ± 0.07 0.61 ± 0.03 0.60 ± 0.07 0.58 ± 0.08 0.64 ± 0.10 0.63 ± 0.09
BUN (mg/dL) CG 30.7 ± 10.9 28.3 ± 5.2 26.7 ± 5.2 26.7 ± 5.1 26.4 ± 3.2 31.0 ± 11.5 29.5 ± 6.8a 31.5 ± 8.8a
WCG 27.4 ± 4.3 30.2 ± 3.1 27.3 ± 4.1 23.0 ± 5.1 26.3 ± 5 26.4 ± 4.2 28.4 ± 10.4 28.0 ± 3.9
mGFR (mL/min/kg) CG 3.92 ± 0.91 3.78 ± 0.73 3.61 ± 0.76 3.27 ± 0.62 4.15 ± 0.81 4.97 ± 1.02 5.33 ± 1.03a
WCG 3.83 ± 0.58 3.53 ± 0.47 3.33 ± 0.38 2.96 ± 0.84 3.79 ± 0.74 4.13 ± 0.67 5.28 ± 1.17
Data are presented as mean ± SD of 8 beagles per group for all time points. The control group (n = 8) was fed to maintain an ideal body weight throughout the study.
The weight-change group (n = 8) was fed to induce obesity (week 0–47), maintain a stable body weight (week 47–56) and to lose weight (week 56–83). mGFR was not
measured during week 68.
aData from one dog missing.
�P = 0–0.001 and §P = 0.001–0.01, after multiple correction, for the group x time interaction.
https://doi.org/10.1371/journal.pone.0231662.t001
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The values of uIgG/c and uNGAL/c increased significantly at week 47 in the weight-change
group compared to the control group (uIgG/c: 10.3 ± 10.7 vs. 52.9 ± 93.3 mg/g, P = 0.044;
uNGAL/c: 1.4 ± 1.4 vs. 12.6 ± 16.8 ng/g, P = 0.006) and decreased from week 56 to 83 (Fig 5C
and 5D). Of all CEUS renal perfusion parameters, only cortical TTP was significantly different.
It was shorter at week 12 (14.8 ± 5.3 vs. 11.2 ± 2.3, P = 0.018) and 24 (15.6 ± 2.9 vs. 10.4 ± 1.6,
P< 0.001) in the weight-change group compared to the control group and gradually increased
from week 36 to 83 (Fig 5F).
Two out of eight dogs in the weight-change group had proteinuria at week 47 (UPC
1.67 ± 0.85) and 56 (UPC 1.53 ± 0.25). Only one of both dogs remained proteinuric at week 83
(UPC 0.95). In the control group, from week 12, one dog had persistent but mild proteinuria
(UPC 0.62 ± 0.14) without azotemia.
Discussion
Obesity increases the risk of developing obesity-related glomerulopathy and chronic kidney
disease in humans [2,37]. Like chronic kidney disease, diagnosing obesity-related kidney
Table 2. Association of serum leptin, biomarkers of kidney function and kidney injury and CEUS renal perfusion variables with body fat (BF) percentage and lean
mass (kg) within the weight-change group in dogs.
BF (%) Lean mass (kg)
Variables Estimate SE P-value Estimate SE P-value
Serum leptin (ng/mL) 4.86 0.49 <0.001 0.25 0.05 <0.001
mGFR (mL/min/kg) -3.85 1.02 0.002 -0.14 0.09 0.387
sCysC (mg/L) 166.52 28.31 <0.001 13.59 2.72 <0.001
UPC 10.37 2.64 0.003 0.39 0.24 0.353
uIgG/c (mg/g) 0.07 0.03 0.035 0 0 0.936
uNGAL/c (ng/g) 0.53 0.12 <0.001 0.03 0.01 0.06
uRBP/c (mg/g) 36.8 15.8 0.1 -0.38 1.6 1
PE -2.7 0.73 0.001 0.07 0.06 0.595
WiAUC -3.49 0.69 <0.001 0 0.06 1
AUC -3.5 0.68 <0.001 -0.01 0.05 1
WoAUC -3.49 0.67 <0.001 -0.02 0.05 1
mTT -1.95 0.81 0.048 -0.01 0.06 1
RT -1.64 0.83 0.17 -0.22 0.06 0.001
TTP -2.7 0.97 0.038 -0.22 0.07 0.013
FT -1.32 0.78 0.289 -0.19 0.06 0.002
WiPI -2.7 0.73 0.001 0.07 0.06 0.603
PE 0.15 0.79 1 0.15 0.05 0.017
WiR 0.99 0.76 0.539 0.17 0.05 0.004
WiPI 0.12 0.79 1 0.15 0.06 0.016
WoR 1.13 0.74 0.357 0.14 0.05 0.018
The weight-change group (n = 8) was fed to induce obesity (week 0–47), maintain a stable body weight (week 47–56) and to lose weight (week 56–83). Urinary C-
reactive protein concentrations were consistently below detection levels. CEUS, contrast-enhanced ultrasound; SE, standard error; mGFR, measured glomerular
filtration rate; sCysC, serum cystatin C; UPC, urinary protein:creatinine ratio; uIgG/c, urinary immunoglobulin G:creatinine ratio; uNGAL/c, urinary neutrophil
gelatinase-associated lipocalin:creatinine ratio; uRBP/c, urinary retinol-binding protein:creatinine ratio; PE, peak enhancement; WiAUC, wash-in area-under-the curve;
AUC, total area-under-the curve; WoAUC, wash-out area-under-the curve; mTT, mean transit time; RT, rise time; TTP, time-to-peak; FT, fall time; WiR, wash-in rate;
WiPI, wash-in perfusion index; WoR, wash-out rate. P < 0.05 was considered significant (bold).
https://doi.org/10.1371/journal.pone.0231662.t002
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disease at an early stage is challenging as routine measures of kidney function might not be
sensitive enough [4]. More sensitive diagnostic techniques to detect kidney injury and changes
in function early on in the disease might be useful in monitoring and maybe prevention of
obesity-related kidney disease [4]. The aim of this study was to assess when and how changes
in kidney function, perfusion and injury occur as dogs gradually became obese and subse-
quently lost weight. This is the first longitudinal study involving obesity development and sub-
sequent weight-loss in the same subject. Evaluation of the kidney was based on routine and
novel markers of kidney function and injury as well as on CEUS as an alternative method to
assess renal perfusion in dogs. An alteration in renal perfusion was observed with CEUS early
in obesity development, prior to increases in the functional marker sCysC, UPC, and novel
biomarkers of glomerular and tubular injury uIgG/c and uNGAL/c, respectively. Moreover,
weight-loss reversed these changes. Additionally, serum leptin was significantly elevated just
Fig 5. Kidney-related parameters of beagles in the control group (closed circles; n = 8) and in the weight-change
group (open circles; n = 8) during the weight-gain phase (week 0–47), weight-stable phase (week 47–56) and
weight-loss phase (week 56–83). Serum cystatin C (sCysC, A), a biomarker of kidney function; urinary protein:
creatinine (UPC) (B), urinary immunoglobulin G:creatinine (uIgG/c, C), a biomarker of renal glomerular injury; and
urinary neutrophil gelatinase-associated lipocalin:creatinine (uNGAL/c, D) a biomarker of renal tubular injury;
urinary retinol-binding protein (uRBP/c, E) and time-to-peak (TTP) of the renal cortex, representing blood velocity,
measured with contrast-enhanced ultrasound (F) are shown. aData from one dog missing in the control group.
���P = 0–0.001, ��P = 0.001–0.01 and �P = 0.01–0.05 for the group x time interaction, after multiple correction.
https://doi.org/10.1371/journal.pone.0231662.g005
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prior to elevations in UPC, uIgG/c and uNGAL/c, which might have played a role in the
observed elevations. Leptin stimulates glomerular endothelial cells proliferation and trans-
forming growth factor-β1 expression/secretion, a profibrinogenic cytokine and contributor to
glomerulosclerosis development [38].
Cortical TTP was significantly shorter in the weight-change group at the beginning of the
weight-gain phase, indicating that the cortex took less time to completely perfuse compared to
the control group. Medullary TTP was not significantly different between the groups and
might be due large with-in dog variation which could be caused by respiratory movement and
the presence of interlobar arteries [25,39,40]. Interestingly, at that time point, the weight-
change group dogs still had an ideal body weight and condition [24], suggesting that even with
slight weight gain (i.e., 11–22%), a physiological response might have occurred paving the way
to kidney damage as suggested by increases uIgG/c and uNGAL/c. With 50% weight-gain in a
porcine model of metabolic syndrome, cortical perfusion (measured by multidetector com-
puted tomography) also increases, accompanied by proliferation of 20- to 40-μm cortical
microvessels and expression of angiogenic activity proteins, e.g., vascular endothelial growth
factor (VEGF) [41]. In contrast, in a murine obesity-related glomerulopathy model, mice with
a 200% increase in body weight have longer cortical TTP, detected by CEUS, with concurrent
capillary density reduction compared to control mice [15]. These studies suggest that when
weight-gain is minimal to 50%, renal cortical perfusion increases, possibly due to angiogenesis.
However, newly-formed microvessels might not function properly yet and instead attract
inflammatory cytokines that partake in initiating renal injury [41]. Furthermore, overexpres-
sion of VEGF is strongly associated with development of glomerular endothelial lesions in obe-
sity-related glomerulopathy patients [42]. Extreme weight-gain can exacerbate hemodynamic,
metabolic and inflammatory changes leading to microvascular rarefaction and kidney injury
[12]. The latter process might have occurred in the weight-change group as urinary biomarkers
of renal injury increased when body weight gain was maximal even though cortical TTP was
no longer significantly different compared to the control group.
Renal TTP, however, can also be influenced by other factors, e.g., heart rate and cardiac out-
put [43]. In the canine model of obesity-induced hypertension, 10% weight-gain increases
heart rate, cardiac output, and blood pressure [44]. However, weight-gain is often induced by
feeding a high amount of fat in canine models of obesity [16–18]. In fact, dogs already show
increased heart rate on the first day of a diet supplemented with beef fat [45]. Therefore, TTP
could also be affected by diet. In the current study, absolute dietary fat intake increased with
food intake in the weight-change group. However, the diet was the same for both groups and
thus the macronutrient ratio remained the same and was not extreme compared to other stud-
ies [16–18]. Furthermore, increased cardiac output in obesity is more strongly correlated with
fat-free body mass than with fat mass [46]. In the weight-change group, lean mass increased
significantly only at the end of the weight-gain phase so cardiac output might have not have
been the main contributor to the change in TTP. Nevertheless, although sBP did not signifi-
cantly differ between the two groups, interpretation of TTP must be made with caution as
heart rate and cardiac output were not measured.
In contrast to many studies involving obesity-related renal disease, mGFR and sBP were
not significantly different between the two groups [16,47]. VEGF might be responsible for
increasing renal blood flow without a concomitant increase in GFR. Not only is VEGF an
angiogenic factor, it is also a vasodilator via nitric oxide synthesis [48]. In a study of the iso-
lated perfused rat kidney, VEGF increased the renal blood flow without a change in glomerular
filtration rate and permselectivity [49]. Furthermore, the protein excretion rate of rats infused
with VEGF into the renal artery was not influenced [49]. Although VEGF is also involved in
the induction of fenestration in endothelial cells, the authors of the study suggest that fenestrae
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expansion of the glomerular endothelia were already maximal and could explain the observa-
tions seen [49]. Moreover, in obese Zucker rats, renal cortical vascularization is increased at an
early stage and accompanied by higher levels of VEGF, which might be a compensatory mecha-
nism to maintain renal perfusion [50]. However, a more likely explanation for our results is
that the weight-gain in the weight-change group was either not pronounced or chronic enough
to induce changes in mGFR. Renal function biomarker sCysC, however, was significantly
increased with weight-gain and decreased with weight-loss. The latter is consistent with a
weight-loss study in obese pet dogs [51]. Although an increase in sCysC suggests a decrease in
kidney function [52], it must be interpreted with caution. In obese humans, concentrations of
sCysC and mRNA expression in adipose tissue are consistently higher, independent of esti-
mated GFR [6]. Moreover, sCysC is significantly associated with body fat % [53], like in our
study. Although this biomarker seems to be unaffected by muscle mass unlike serum creatinine
[53], our study found a significant association with lean mass, similar to another study [54].
Our study confirmed that obesity increases urinary protein excretion as body fat % was also
significantly associated with UPC [2]. However, it is also in contrast to a pet dog study in
which UPC values between lean and obese animals did not significantly differ [41,55]. The lim-
ited number of obese and severely obese pet dogs recruited might have been a factor in the dis-
crepancy. Furthermore, although UPC also decreased with weight-loss, similar to previous
canine and human studies [3,51], the extent to which the kidneys experienced injury remains
to be documented. The two proteinuric weight-change group dogs during the study were still
proteinuric approximately 6 months after the study ended despite a lean body weight and no
other relevant clinical abnormalities.
While UPC is useful in assessing renal function in combination with other routine bio-
markers, it lacks specificity regarding identification of both the cause and location of renal
injury [56]. Studies using site-specific biomarkers of renal injury in obesity are limited. In the
current study, two glomerular and two tubular biomarkers of renal injury were evaluated.
Unexpectedly, only one of each type (uIgG/c and uNGAL/c, respectively) was significantly
increased at the end of the weight-gain phase in the weight-change group. The severity of the
induced kidney lesions might partly explain this finding. For example, in patients with rheu-
matoid arthritis and renal amyloidosis, uCRP is only measurable in combination with heavy
proteinuria (i.e., >3 g/24 h) [57]. As uCRP was undetectable in the samples of our study,
uIgG/c might be a more sensitive biomarker for early or mild glomerular injury. If used in
combination with other urinary biomarkers, uCRP/c might still be useful in determining the
severity of glomerular damage.
uNGAL/c significantly increased in the weight-change group at the end of the weight-gain
phase. However, in other studies uNGAL/c values are inconsistent in obese subjects, reflecting
discrepancies in the type of lesions found (i.e., glomerular or tubular only or both) [58–63].
The combined increase in UPC, uIgG/c and uNGAL/c suggests a degree of permeability defect
and tubular injury during the weight-gain phase. However, uRBP/c, the other tubular bio-
marker, did not change significantly over time. For uRBP levels to increase, an impairment in
the glomerular filtration barrier causing competition for the reabsorption of proteins, massive
production of low-molecular weight proteins that surpasses the capacity of proximal tubular
reabsorption, or impairment of the reabsorption machinery has to occur [64]. In this study, it
might be possible that the degree of the permeability defect was too low in the weight-change
dogs to have caused competition for reabsorption and that the proximal tubular cells still had
the capacity to reabsorb protein. However, the levels of high-molecular weight proteins, such
as uIgG, was probably high enough to cause expression and detectable increases of uNGAL, as
exposure of the proximal tubular epithelial cells to such proteins stimulates inflammatory
responses and apoptosis [65–67]. Damaged tubular cells respond by actively producing
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uNGAL as a defense mechanism to counteract intracellular oxidative stress and complement-
induced apoptosis [66].
The current study has some limitations. First, because of its invasiveness, no renal biopsies
were performed. Histopathologic examination of biopsies might confirm or dispute the
observed urinary biomarkers changes. Similarly, tissue studies assessing the renal microvascu-
lature and expression of VEGF could also have been useful. The main reasons renal biopsies
were not performed were 1) ethical considerations, as the most common complication is
severe hemorrhage, and complications are more likely to occur in dogs between 4 to 7 years or
greater than 9 years, like the majority of the dogs in our study [68]; and 2) as this was a longitu-
dinal study, there is a possible risk that persistent iatrogenic lesions in the kidney due repeated
biopsies could occur [69] and could confound the findings of the kidney injury markers. In a
previous study, worsening histologic changes, such as glomerulosclerosis and interstitial fibro-
sis after repeated biopsies in dogs (8.4 to 11 years) were found [70]. However, it is not clear
whether the changes could be attributed to the biopsies or to age-related lesions or progression
of existing lesions. Furthermore, the scope of the study was to assess whether non-invasive
techniques such as CEUS and novel renal biomarkers could provide extra information beyond
that of routine measures on kidney function and injury potentially induced by obesity.
Second, a gold standard for measuring renal blood flow was not used in this study.
Although measuring para-amino hippuric acid clearance is considered the gold standard to
estimate renal plasma flow, is moderately correlated to CEUS in humans (r = 0.69) [71]. Fur-
thermore, currently, there is no gold standard for assessing microperfusion, as para-amino
hippuric acid clearance is a measure of global renal perfusion [72].
Third, because the study lasted 1.5 years, functional and structural changes of the kidney,
e.g., proteinuria and glomerulosclerosis, as a consequence of aging must also be considered
[73]. However, the CG was age-matched, so age-related changes are expected to occur equally
in both groups.
Fourth, CEUS is vulnerable to variation caused by differences in e.g., scanner settings, the
contrast agent used, and patient-related factors [43]. Part of this variation can be overcome by
using a standardized protocol, as was done for this study, but patient-related factors are more
difficult to control [43]. Intra-individual variation of CEUS perfusion parameters using a stan-
dardized protocol, with an interval between 9 and 27 weeks, in dogs was very similar to the
variation found in cats that were examined with 7-day intervals [25,39]. Nevertheless, variation
for varies widely for the perfusion parameters with TTP of the cortex having the least amount
of variation across time (coefficient of variation of 15%) [25].
Fifth, differences in sodium intake between the two groups could have affected hemody-
namics. As obesity was induced by increasing the amount of the same feed, sodium intake was
most likely higher during the weight gain phase of the weigh-change group (S2 Table). While
an increase in blood pressure, volume and flow after receiving a diet containing high amounts
of sodium (4 g/kg body weight) have been seen in an experimental study using dogs, the
sodium content was considerably higher than what the dogs received in our study [74]. Dogs
are able to tolerate a wide range of sodium concentrations in the diet as long as access to water
remains available [75].
Although the study had random, age-matched groups, there could have been other parame-
ters might have had an influence on the outcome parameters. However, because of the small
sample size, it is difficult to fully explore them. Larger studies in the future would be helpful in
detecting other confounding factors.
Lastly, this study used diet-induced obese dogs. Because the duration that dogs remained
obese was relatively short, cut-off points cannot be made and the results cannot be extrapo-
lated to humans. Furthermore, it is unknown if CEUS and the selected novel renal biomarkers
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are also useful in human obesity. However, the potential exists as dogs are good models of obe-
sity and obesity-related glomerulopathy in humans due to similarities in fat accumulation,
genetic background and comorbidities [76,77]. Furthermore, previous experiments have
shown that demonstrate that when dogs are used as a model for obesity-induced hypertension
or obesity-induced renal disease, hemodynamic changes closely mimic those of obese humans,
such as an increase in arterial blood pressure, GFR, and renal blood flow [16,23,76]. The rea-
son our study did not observe increased blood pressure and GFR during the weight-gain phase
is unclear. The major differences compared to the previous studies are that those studies
induce weight-gain at a faster rate and the dogs are fed a diet high in fat or supplemented with
fat.
In conclusion, CEUS detected alterations in renal perfusion early in obesity development in
dogs, without hyperfiltration and prior to increases in biomarker concentrations of kidney
function (i.e., sCysC) and injury (i.e., uIgG/c and uNGAL/c); and is reversed with weight-loss.
The results of this study can serve as a starting point for studies in human obesity-related kid-
ney disease and for the development of more sensitive and non-invasive techniques to detect
early alterations in kidney function, perfusion and injury. Combining CEUS and urinary bio-
markers to monitor renal function and injury might be more sensitive in identifying and
monitoring individuals at-risk for obesity-related glomerulopathy than traditional techniques
alone. Future studies should investigate the clinical applicability of CEUS and the selected uri-
nary kidney injury and serum functional biomarkers in overweight and obese individuals.
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S1 Video. Contrast-enhanced ultrasonography of the left canine kidney in the longitudinal
plane. This recording demonstrates the first 20 seconds after a bolus injection of sulfur hexa-
fluoride-filled microbubbles (SonoVue1, Bracco Diagnostics Inc., Milan, Italy).
(MP4)
S1 Table. Analyzed nutrient composition of the commercial canine adult maintenance
diet�. NFE, nitrogen- free extract; TDF, total dietary fiber; IDF, insoluble dietary fiber; SDF,
soluble dietary fiber; ME, metabolizable energy �Diet ingredients, Virbac Veterinary™ HPM
Adult Large and Medium: Dehydrated pork and poultry protein, rice (min. 7%), whole pea,
animal fat, hydrolyzed animal protein, potato starch (min. 4%), lignocellulose, linseed field
bean hulls, mineral salts, beet pulp, fructo-oligosaccharides, psyllium fiber, chitosan, pasteur-
ized Lactobacillus acidophilus, chondroitin sulfate. §Calculated as 100 − (crude protein + crude
fat + crude ash + crude fiber) †Estimated using a four-step calculation [27].
(DOCX)
S2 Table. Body characteristics and kidney-related measurements over time of dogs in the
control group (CG) and the weight-change group (WCG). Data are presented as mean ± SD
of 8 beagles per group for all time points. Beagles in the control group (n = 8) were fed to main-
tain an ideal body weight throughout the study. The weight-change group (n = 8) was fed to
develop obesity (week 0–47), to maintain a stable body weight (week 47–56) and to lose weight
(week 56–83). aData from one dog missing. bFat mass and sodium intake were not included in
the statistical analysis. BW, body weight; UPC, urine protein:creatinine ratio; sCysC, serum
cystatin C (sCysC); uRBP/c, urinary retinol-binding protein:creatinine ratio; uNGAL/c, uri-
nary neutrophil gelatinase-associated lipocalin:creatinine; uIgG/c, urinary immunoglobulin G:
creatinine. �P = 0–0.001, §P = 0.001–0.01 and †P = 0.01–0.05, after multiple correction, for the
group x time interaction.
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S3 Table. CEUS renal perfusion variables from the left kidney over time in dogs from the
control group (CG) and the WG group (WCG). Data are presented as mean ± SD of 8 bea-
gles per group for all time points. Beagles in the control group (n = 8) were fed to maintain an
ideal body weight throughout the study. The weight-change group (n = 8) was fed to develop
obesity (week 0–47), to maintain a stable body weight (week 47–56) and to lose weight (week
56–83). aData from one dog missing at week 24 and week 83. PE, peak enhancement; WiAUC,
wash-in area under the curve; AUC, total area under the curve; WoAUC, wash-out area under
the curve; mTT, mean transit time; RT, rise time; TTP, time-to-peak; FT, fall time; WiR, wash-
in rate; WiPI, wash-in perfusion index; WoR, wash-out rate. �P = 0–0.001, §P = 0.001–0.01
and †P = 0.01–0.05, after multiple correction, for the group x time interaction.
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